Skip to main content
Premium Trial:

Request an Annual Quote

Aventis, Millennium in $450 M Deal

Premium

Aventis Pharma, the pharmaceutical unit of Aventis, has said it would pay Millennium Pharmaceuticals $450 million for a stake in the company as well as for the rights to its drug discovery technologies.

 

Under the terms of the deal, Aventis will pay Millennium of Cambridge, Mass., up to $200 million over a five-year period in exchange for the rights to its technologies. Aventis of Frankfurt, will also buy up to $250 million in Millennium’s common stock. A $150 million stock purchase is to be made at the closing of the deal and two $50 million purchases will be made in 2001.

 

The two companies said they would work together to develop new technologies along with anti-inflammatory drugs aimed at treating rheumatoid arthritis, asthma and chronic obstructive pulmonary disease, multiple sclerosis, and inflammatory bowel disease.

 

Filed under

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.